ReviewFrontiers in medicine2026
Molecular profiles of red blood cells across geographic, pathological, and age-related perspectives: translational insights.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Red blood cells (RBCs), formerly viewed as mere oxygen transporters, are now acknowledged as dynamic biological entities with intricate molecular characteristics which impact their deformability, lifespan, and interactions within the vascular system. Progress in molecular hematology has elucidated how modifications in RBC proteins, lipids, ion channels, and adhesion molecules influence physiological adaptability, pathogenic mechanisms, and transfusion results. Inherited and acquired illnesses, such as sickle cell disease, thalassemia, malaria, human immunodeficiency virus (HIV), and metabolic disorders, highlight how alterations in membrane structure, phospholipid asymmetry, and signaling pathways exacerbate hemolysis, restrict circulation, and provoke inflammation or thrombosis. Geographic and environmental pressures, such as hypoxia at elevated altitudes, emphasize the variety of molecular methods that facilitate oxygen delivery. The integration of these insights into clinical practice reveals that molecular markers such as Band 3, PIEZO1, ICAM-4, CD36, and CD47 are becoming significant diagnostic and prognostic instruments, while targeted therapies focusing on ion channels, oxidative pathways, and adhesion molecules are creating new therapeutic possibilities. These results highlight that RBC molecular profiling is enhancing our comprehension of erythrocyte biology while also transforming diagnostics, transfusion medicine, and customized therapy in hematology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.